Skip to content
Back
News Coverage

Tessa Therapeutics, Parker Institute partner to jointly advance research in cancer immunotherapy

Tessa Therapeutics, a fully-integrated, international biotech company, and the Parker Institute for Cancer Immunotherapy has announced the establishment of a multi-year strategic alliance to combine their capabilities to jointly advance research in the field of cancer immunotherapy. The two partners will collaborate on unique clinical and pre-clinical projects in order to develop novel cellular therapy and immuno-oncology combination treatments.

The Parker Institute’s model brings together top cancer research institutions to share resources, data, and technology, accelerate research through unifying and managing clinical trial design, and conduct multi-center clinical trials.

Read More

Get Email Updates